Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Given Consensus Rating of “Buy” by Brokerages

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPHGet Rating) has earned a consensus recommendation of “Buy” from the six analysts that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $36.67.

AMPH has been the topic of several recent research reports. StockNews.com initiated coverage on shares of Amphastar Pharmaceuticals in a research report on Thursday, March 31st. They set a “buy” rating on the stock. Zacks Investment Research cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday. Wells Fargo & Company upped their target price on shares of Amphastar Pharmaceuticals from $23.00 to $32.00 and gave the company an “equal weight” rating in a research report on Tuesday, March 15th. Northland Securities increased their price target on shares of Amphastar Pharmaceuticals from $33.00 to $43.00 in a research report on Monday, April 11th. Finally, Piper Sandler increased their price target on shares of Amphastar Pharmaceuticals from $28.00 to $35.00 and gave the stock an “overweight” rating in a research report on Friday, March 11th.

In related news, Director Michael A. Zasloff sold 10,291 shares of the stock in a transaction on Monday, May 16th. The shares were sold at an average price of $35.61, for a total value of $366,462.51. Following the transaction, the director now directly owns 47,206 shares of the company’s stock, valued at approximately $1,681,005.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Floyd F. Petersen sold 9,924 shares of the business’s stock in a transaction on Wednesday, May 18th. The shares were sold at an average price of $35.05, for a total transaction of $347,836.20. Following the completion of the sale, the director now directly owns 86,445 shares of the company’s stock, valued at $3,029,897.25. The disclosure for this sale can be found here. Insiders have sold 39,410 shares of company stock worth $1,365,991 over the last 90 days. Insiders own 27.80% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Lido Advisors LLC purchased a new stake in Amphastar Pharmaceuticals in the first quarter valued at $492,000. Point72 Hong Kong Ltd purchased a new stake in Amphastar Pharmaceuticals in the first quarter valued at $74,000. Royal Bank of Canada lifted its position in Amphastar Pharmaceuticals by 257.2% in the first quarter. Royal Bank of Canada now owns 26,585 shares of the company’s stock valued at $954,000 after acquiring an additional 19,142 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Amphastar Pharmaceuticals in the first quarter valued at $251,000. Finally, Eqis Capital Management Inc. purchased a new stake in shares of Amphastar Pharmaceuticals in the first quarter valued at about $307,000. 59.79% of the stock is owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals stock opened at $33.70 on Friday. The company has a fifty day simple moving average of $36.44 and a 200-day simple moving average of $28.19. The company has a quick ratio of 2.35, a current ratio of 3.19 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $1.65 billion, a price-to-earnings ratio of 20.93 and a beta of 0.66. Amphastar Pharmaceuticals has a 52-week low of $17.56 and a 52-week high of $44.46.

Amphastar Pharmaceuticals (NASDAQ:AMPHGet Rating) last announced its quarterly earnings results on Tuesday, May 10th. The company reported $0.47 earnings per share for the quarter, beating the consensus estimate of $0.36 by $0.11. Amphastar Pharmaceuticals had a net margin of 17.87% and a return on equity of 17.35%. During the same quarter in the previous year, the business posted $0.27 EPS. On average, research analysts anticipate that Amphastar Pharmaceuticals will post 1.41 EPS for the current fiscal year.

About Amphastar Pharmaceuticals (Get Rating)

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API.

Read More

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.